Genomics and Precision Medicine

This basket targets the genomics and precision medicine theme, which harnesses advances in gene editing, targeted gene therapies, and personalized treatments to address genetic disorders, rare diseases, and oncology with high unmet needs. The 20-name portfolio spans biotechnology and healthcare sectors, with concentrated exposure to CRISPR-based editing, redosable gene delivery platforms, and next-generation CAR-T cell therapies. The investment logic rests on the sector's structural tailwinds: the global precision medicine market is projected to expand from approximately $119 billion in 2025 to over $500 billion by 2035 at a CAGR exceeding 16%, driven by approved therapies generating commercial revenue, accelerating clinical pipelines, and declining sequencing costs that enable broader adoption. With an effective N of 19.5 indicating low concentration risk despite equal top weights, the basket captures both near-term revenue inflection from marketed products and longer-term upside from transformative one-time or redosable interventions.

Key risks include clinical trial failures, manufacturing scalability challenges for autologous and ex vivo therapies, regulatory hurdles around long-term safety monitoring, and reimbursement pressures for high-cost treatments. Specific warnings highlight cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies associated with certain CAR-T approaches, alongside potential off-target genomic effects and chromosomal instability from gene-editing tools. The highest-conviction position is CRSP at 6.1% weighting, as CRISPR Therapeutics leads with CASGEVY, the first approved CRISPR-based therapy already demonstrating launch momentum and multi-billion-dollar potential in hemoglobinopathies, supported by a diversified pipeline across oncology, regenerative medicine, and autoimmune indications that positions it for multiple data readouts and revenue acceleration in 2026.